`Argentum Pharm. LLC v. Alcon Research, Ltd.
`Case IPR2017-01053
`
`
`
`4.
`
`I have never been suspended or disbarred from practice before any
`
`court or administrative body.
`
`5.
`
`No court or administrative body has ever denied my application for
`
`admission to practice before it.
`
`6.
`
`No court or administrative body has ever imposed sanctions or
`
`contempt citations on me.
`
`7.
`
`I have read and Will comply with the Office Patent Trial Practice
`
`guide and the Board’s Rules of Practice for Trials set forth in part 42 of 37 C.F.R.
`
`8.
`
`I understand that I will be subject to the USPTO Code of Professional
`
`Responsibility set forth in 37 C.F.R. §§ 11.101 et seq. and will be subject to
`
`disciplinary jurisdiction under 37 C.F.R. § 11.19(a).
`
`9.
`
`I have applied to appear pro hac vice in eight (8) other proceedings
`
`before the Office in the last three (3) years: (1) Hospira, Inc. v. Genentech, Inc.,
`
`IPR2016-01 83 7, challenging US. Patent No. 7,807,799; (2) Hospira, Inc. v.
`
`Genentech, Inc. , IPR2016-01771, challenging US. Patent No. 7,622,1 15; (3)
`
`Argentum Pharmaceuticals LLC v. Alcon Research, Ltd, IPR2016-00544,
`
`challenging US. Patent No. 8,791,154; (4) Sandoz Inc. v. Eli Lilly & C0.,
`
`IPR2016-00318, challenging US. Patent No. 7,772,209; (5) Neptune Generics,
`
`LLC v. Eli Lilly & C0. , IPR2016—00240, challenging US. Patent No. 7,772,209; (6)
`
`Neptune Generics, LLC v. Eli Lilly & C0., IPR2016-00237, challenging U.S.
`
`
`
`Patent No. 7,772,209; (7) Accord Healthcare Inc. et al. v. Daiichi Sankyo Co. et
`
`al. , IPR2015-00865, challenging US. Patent No. 8,569,325; (8) Accord Healthcare
`
`Inc. et a]. v. Daiichi Sankyo Co. et al., IPR2015-00864, challenging US. Patent
`
`No. 8,404,703.
`
`10.
`
`I am familiar with the subject matter at issue in the present
`
`proceeding.
`
`I was lead trial counsel for Alcon in litigation in the US. District
`
`Court for the District of Delaware in which the same patent was at issue: Alcon
`
`Research, Ltd. v. Mylan Pharmaceuticals Inc. & Mylan Inc. , No. 1:13-cv-01332
`
`(SLR); Alcon Research, Ltd. v. Wockhardt Ltd, Wockhardt Bio AG, & Wockhardt
`
`USA, LLC, No. 1:13—cv-02040 (SLR); Alcon Research, Ltd. v. Illicro Labs Ltd. &
`
`Micro Labs USA Inc., No. 1:14-cv-00014 (SLR); and Alcon Research, Ltd. v.
`
`Watson Laboratories, Inc. et al., No. 1:14—cv-00647 (SLR). In addition, I
`
`previously represented Alcon before the Patent Trial and Appeal Board in Apotex
`
`Corp. v. Alcon Research, Ltd., IPR2013-00428, which challenged the same patent
`
`at issue here.
`
`11.
`
`I hereby declare that all statements made herein of my own
`
`knowledge are true and that all statements made on information and belief are
`
`believed to be true, and further that these statements were made with the
`
`knowledge that willful false statements and the like so made are punishable by fine
`
`or imprisonment, or both, under 18 U.S.C. § 1001.
`
`
`
`Adam L. Perlman
`
`